Table 3 |
||||
|
Racial differences in average adherence to oral antidiabetic medication over a 24-month follow-up period |
||||
|
Sulfonylurea (n = 1256) |
Metformin (n = 148) |
|||
|
|
||||
|
Time Since First Prescription |
Incidence Rate Ratio |
95% Confidence Interval |
Incidence Rate Ratio |
95% Confidence Interval |
|
|
||||
|
Across All Quarters (Blacks vs. Whites) |
0.96 |
0.89, 1.05 |
0.79 |
0.63, 0.99† |
|
|
||||
|
Within Quarters (Blacks vs. Whites) |
||||
|
Quarter 1 |
1.00 |
0.92,1.09 |
0.78 |
0.80, 1.00 |
|
Quarter 2 |
0.86 |
0.78, 0.96† |
0.86 |
0.65, 1.13 |
|
Quarter 3 |
0.90 |
0.80, 1.00 |
0.92 |
0.69, 1.21 |
|
Quarter 4 |
0.91 |
0.81, 1.02 |
0.72 |
0.49, 1.06 |
|
Quarter 5 |
0.94 |
0.84, 1.05 |
0.63 |
0.41, 0.96† |
|
Quarter 6 |
0.92 |
0.81, 1.03 |
0.83 |
0.59, 1.17 |
|
Quarter 7 |
0.92 |
0.81, 1.05 |
0.69 |
0.45, 1.06 |
|
Quarter 8 |
0.96 |
0.84, 1.04 |
0.59 |
0.35, 0.97† |
|
|
||||
|
Adjusted for age, gender, neighborhood socioeconomic status, body mass index, any HbA1c test, baseline glycemic level, number of MD visits, and number of comorbidities, health centers with disproportionately high numbers of black patients; Referent Group: initiation month of treatment group; All rates reflect both main effect of race and quarter effects. †p < .05 |
||||
|
Trinacty et al. BMC Health Services Research 2009 9:24 doi:10.1186/1472-6963-9-24 |
||||
